As Biotechnology businesses, CRISPR Therapeutics AG (NASDAQ:CRSP) and Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM), are affected by contrast. This especially applies to their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||59||0.00||34.37M||-0.46||0.00|
|Bellicum Pharmaceuticals Inc.||1||0.00||41.95M||-2.45||0.00|
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 demonstrates the return on equity, return on assets and net margins of CRISPR Therapeutics AG and Bellicum Pharmaceuticals Inc.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||58,512,087.16%||-2.6%||-2%|
|Bellicum Pharmaceuticals Inc.||4,630,753,946.35%||-293.5%||-97.7%|
The current Quick Ratio of CRISPR Therapeutics AG is 8.3 while its Current Ratio is 8.3. Meanwhile, Bellicum Pharmaceuticals Inc. has a Current Ratio of 1.4 while its Quick Ratio is 1.4. CRISPR Therapeutics AG is better positioned to pay off its short-term and long-term debts than Bellicum Pharmaceuticals Inc.
CRISPR Therapeutics AG and Bellicum Pharmaceuticals Inc. Ratings and Recommendations are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Bellicum Pharmaceuticals Inc.||0||0||0||0.00|
CRISPR Therapeutics AG has a consensus target price of $72, and a 10.16% upside potential.
Institutional & Insider Ownership
Institutional investors owned 46.8% of CRISPR Therapeutics AG shares and 35.7% of Bellicum Pharmaceuticals Inc. shares. Insiders owned 0.4% of CRISPR Therapeutics AG shares. Insiders Competitively, owned 0.2% of Bellicum Pharmaceuticals Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Bellicum Pharmaceuticals Inc.||-6.6%||-36.72%||-36.22%||-61.06%||-80.99%||-72.26%|
For the past year CRISPR Therapeutics AG has 153.31% stronger performance while Bellicum Pharmaceuticals Inc. has -72.26% weaker performance.
On 7 of the 10 factors CRISPR Therapeutics AG beats Bellicum Pharmaceuticals Inc.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The companyÂ’s preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino GesÃº for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.